Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

The therapeutic options for patients with noninvasive or invasive breast cancer are complex
and varied. These NCCN Clinical Practice Guidelines for Breast Cancer include …

Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …

Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …

Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in
breast cancer, has limited value for treatment decisions due to questionable analytical …

Despite being the hallmark of cancer that is responsible for the highest number of deaths,
very little is known about the biology of metastasis. Metastatic disease typically manifests …

Abstract Background World Health Organization expert groups recommended mortality trials
of four repurposed antiviral drugs—remdesivir, hydroxychloroquine, lopinavir, and interferon …

Background For women with early-stage oestrogen receptor (ER)-positive breast cancer,
adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors …